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Abstract The effect of neutrophil elastase on the functional 
status of gelatinases was studied in an hamster model developed 
by intratracheal administration of lipopolysaccharide followed by 
in situ cell activation with phorbol myristate acetate. This 
resulted in the production in bronchoalveolar lavage fluids, in 
addition to the matrix metalloproteinase MMP-9, of a 75 kDa 
gelatinase associated with collagenolytic activity. Treatment in 
vivo with an elastase inhibitor abolished the latter activity. Since, 
in addition, elastase activates in vitro purified MMP-9 gelatinase 
into a similar 75 kDa entity, these data suggest that elastase may 
be a physiological activator of MMP-9 in vivo. 
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1. Introduction 
Extracellular matrix (ECM) degradation by specific en-
zymes is thought to play a causative role in lung diseases as 
diverse as emphysema, fibrosis and acute respiratory distress 
syndrome (ARDS) [1]. Neutrophils may contribute to acute 
and chronic lung injury by releasing numerous factors espe-
cially proteolytic enzymes which are able to destroy important 
structural proteins of the lung [2]. Considering the massive 
influx of neutrophils and the increased elastolytic activity in 
bronchoalveolar lavage (BAL) fluid from patients with 
A R D S , it has been suggested that neutrophil elastase may 
play an important role in the pathogenesis of high-permeabil-
ity lung oedema [3]. In addition to elevated levels of neutro-
phil elastase, neutrophil-derived collagenase has also been de-
tected in BAL fluid from patients with A R D S , and MMP-9 
gelatinase (a matrix metalloproteinase) levels in BAL have 
been shown to increase during the course of A R D S [4]. 
MMP-9 also might be a major factor in facilitating migration 
of neutrophils across basement membranes [5]. Gelatinase ac-
tivities have also been demonstrated in different animal mod-
els of acute lung injury. For example, increases in gelatinase 
(MMP-2 and MMP-9) activities were observed in the BAL 
from rats exposed to ozone [6]. Similarly, when lipopolysac-
charide (LPS) is used to induce acute lung injury in a guinea 
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pig model, a total increase in M M P - 9 gelatinase proform ex-
pression was observed [7]. In a rat model of acute alveolitis 
induced by intra-pulmonary deposition of immune complexes, 
when recombinant TIMP-2 (tissue inhibitor of matrix metal-
loproteinase-2) is instilled intratracheally, lung damage is sig-
nificantly reduced [8]. This suggests a functional role of 
M M P s in the process. 
M M P s must be activated to ensure extracellular matrix 
substrate degradation. Although products of the respiratory 
burst, such as hypochlorous acid, can activate M M P s , includ-
ing M M P - 9 [9], the in vivo relevance of this activation mech-
anism remains speculative [10]. Therefore, the use of animal 
models of acute lung injury might be helpful to identify the 
physiological mechanisms leading to M M P activation. 
To further investigate the potential functional role of the 
M M P - 9 gelatinase in lung injury, a model of massive P M N 
recruitment followed by an exogenous cell activation was 
chosen. Neutrophil (PMN) recruitment and activation were 
achieved by treating hamsters intratracheally with LPS fol-
lowed by phorbol myristate acetate (PMA). Gelatinolytic ac-
tivities and their functional status were studied in this model, 
with a particular emphasis on the potential role of neutrophil 
elastase as a gelatinase activator. 
2. Materials and methods 
2.1. Animal treatment 
Ten-week-old male Syrian golden hamsters (Harlan, Zeist, The 
Netherlands), weighing 110-130 g were challenged for 30 min with 
aerosolised lipopolysaccharide (LPS, E. coli 026 :B6, Difco, Detroit, 
MI), 500 u.g/ml dissolved in 0.9% saline, delivered by a compressed air 
nebulizer at 11 1/min in a 10 1 chamber. Control group inhaled saline 
only. Twenty-four hours after LPS inhalation, hamsters, under iso-
flurane anaesthesia, were instilled intratracheally with the S 18465 
elastase inhibitor [11] at the concentration of 300 nmol/hamster, or 
with saline, under 0.2 ml. Three hours after this injection, the animals 
were further injected, again intratracheally, with 0.1 ml PMA (500 ug/ 
kg) in 20% DMSO. A bronchoalveolar lavage was performed 3 h after 
PMA administration. 
2.2. BAL recovery and analyses 
Lungs were washed gently using a single 3 ml aliquot of 0.9% saline 
in a 5 ml syringe, yielding a final volume of approximately 2.5 ml of 
BAL fluid from each animal. 
The amount of blood in each BAL sample was determined by using 
the Boehringer Mannheim Diagnostica kit for haemoglobin. BAL was 
centrifuged at 200 Xg for 10 min at 4°C. The cell pellets were counted 
using a Coulter Counter (Coultronic, Margency, France) and differ-
ential cell counts from at least 200 leukocytes were performed after 
cytocentrifugation with a Cytospin (Shandon, Runcorn, UK). The 
supernatants were routinely stored at —25°C since this procedure 
was not found to alter the enzymatic profiles as compared to freshly 
analysed samples. 
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2.3. Zymography 
Gelatinolytic or caseinolytic activities were detected by zymogra-
phy, as described [12]. Briefly, aliquots of BAL fluid underwent elec-
trophoresis in polyacrylamide gels containing either 1 mg/ml gelatin 
or 1.5 mg/ml casein (both from Sigma) in the presence of SDS under 
non-reducing conditions. After electrophoresis, gels were washed twice 
in 2.5% Triton X-100 for 1 h, rinsed briefly in 50 mM Tris-HCl (pH 
7.4), and incubated at 37°C for 24 h in a buffer containing 50 mM 
Tris-HCl (pH 7.4) and 5 mM CaCl2. The gels were then stained with 
Coomassie Brillant Blue R250. Zones of enzymatic activity were de-
tected as clear bands against a blue background. 
2.4. Type IV collagen degradation assay 
Collagenolytic activity was measured with 3H-labelled type IV col-
lagen (NEN) (37 Kbq/1 (ig) as substrate [13]. BAL and inhibitors were 
added to solutions containing the radiolabelled substrate and incu-
bated for 20 h at 37°C in 0.5 M Tris-HCl, 0.2 M NaCl, 5 mM CaCl2, 
0,02% Brij35, pH 7.5. Substrate hydrolysis was analysed by SDS 
PAGE (gradient 4-20%) and autoradiography. 
2.5. Fluorogenic enzymatic assay 
The peptidomimetic substrate Dnp-Pro-Cha-Gly-Cys(Me)-His-
Ala-Lys(Nma)NH2 (BACHEM, Voisins-le-Bretonneux, France) 
which is cleaved between amino acids Gly and Cys by MMP-9 [14], 
was used to assay the functional activity of purified human recombi-
nant MMP-9 (from Dr. Gillian Murphy, Strangeways Laboratory, 
Cambridge, UK). MMP-9 at a concentration of 1.3 ug/ml was acti-
vated with 2 mM APMA in 0.1 N NaOH at 37°C for 1 h or by 180 
ng/ml human elastase (Elastin Products Company, Inc., Owensville, 
MO) for 24 h. 
The assays were performed in 50 mM Tris-HCl, 200 mM NaCl, 
5 mM CaCl2, 0.1% Brij35, pH 7.7, containing 130 ng/ml purified 
MMP-9, started with 20 uM of substrate and incubated at 37°C for 
10 min. The fluorescent product of cleavage was measured with a 
cytofluorimeter (Cytofluor 2350, Millipore, Saint-Quentin en Yvelines, 
France) equipped with a combination of 340 nm and 440 nm filters 
for excitation and emission, respectively. 
2.6. Elastase activity 
The elastase activity of the BAL fluid was measured using a syn-
thetic elastase substrate: methoxy succinyl-Ala-Ala-Pro-Val-p-nitro-
anilide, according to Virca et al. [15]. Briefly 0.1 ml of BAL fluid 
supernatant was mixed with 0.9 ml of 0.1 M Tris-HCl buffer, pH 
7.8, 0.5 M NaCl. The optical density was read at 410 nm during 30 
min at 37°C with a Unicam spectrophotometer (Cambridge, UK). 
3. Results 
3.1. Cytology and haemoglobin content of BAL 
BAL fluids of four different groups of hamsters were 
studied. The first two groups were composed of animals 
treated (group 2) or not (group 1) intratracheally with P M A 
3 h before lavage. The BAL cell populat ion of these animals 
was essentially composed of macrophages (Table 1). 
The third and fourth group of animals were initially treated 
intratracheally with LPS 24 h before lavage recovery. Massive 
P M N recruitment accounted in both groups for most of the 
increase in total cell number observed as compared to control 
animals (Table 1). The fourth group, in addition to LPS in-
stillation, was further treated intratracheally, 3 h before BAL, 
with PMA to activate resident and recruited cells. Haemoglo-
Table 1 
Cytology and lung injury parameter 
PMN number X 106/BAL % of t( 
Control 0.88 ±0.13 7 ±4 
Control PMA 0.65 ± 0.07 37 ± 11 
LPS 9.79 ±1.73 85 ±4 
LPS+PMA 3.09±0.81 91 ±2 
Fig. 1. A: Gelatin zymography of BAL fluids. BAL from a control 
animal; BAL from one animal treated with PMA 3 h before lavage; 
BAL from a LPS-treated animal; BAL from a hamster treated se-
quentially with LPS and PMA. Samples of 10 ul of crude BAL 
were deposited. B: Zymogram of BAL fluids activated for 1 h with 
APMA. 
bin, a marker of acute lung injury, increased only in the 
fourth group (Table 1). 
3.2. Zymographic analyses of gelatinase activities 
Gelatin zymograms of control hamster BAL fluids demon-
strated that negligible amounts of gelatinases were secreted, 
mainly in the 63, 65 and 92 k D a forms (Fig. 1A). BAL fluids 
from animals treated with PMA only exhibited an increase in 
63, 65 and 92 k D a activities, the 92 k D a gelatinase being now 
clearly detectable (Fig. 1A). After LPS treatment and in the 
absence of P M A , the gelatinolytic activities detected at 63, 65 
and 92 k D a were slightly increased as compared to control 
cell population Haemoglobin g/100 ml/BAL n 
0.043 ±0.001 5 
0.093 ±0.02 5 
0.066 ±0.013 5 
0.540 ±0.165 10 
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Table 2 
Elastase levels in BAL fluids 
ADO/ml/BAL 
Control 
Control PMA 
LPS 
LPS PMA 
0.0014 ±0.0002 
0.0009 ±0.0003 
0.0004 ±0.0003 
0.0227 ±0.0069 
5 
5 
5 
10 
Fig. 2. Effect of in vivo treatment of animals with S 18465 on the 
gelatinolytic activity profile of LPS plus PMA-treated animals. 
hamsters, the 92 kDa activity being predominant (Fig. 1A). 
After a sequential treatment with LPS and PMA, an overall 
increase in gelatinotytic activity was observed, in particular at 
92 kDa, and a new activity appeared at 75 kDa (Fig. 1A). The 
observed activities all required divalent cations and were in-
hibited by EDTA, indicating that they belong to the MMP 
family (not shown). Zymography was carried out with BAL 
samples incubated in the presence of APMA to activate the 
MMPs prior to SDS-PAGE. The observed profile of BAL 
from LPS-treated animals was suggestive of the activation 
of the major 92 kDa species into a 78 kDa entity (Fig. IB). 
In the sample from LPS plus PMA-treated animals the same 
78 kDa activity appeared whereas the 75 kDa activity pro-
gressively disappeared (Fig. IB). No caseinolytic activity 
could be detected by zymography in a buffer devised to reveal 
MMP activity, showing that there was no interstitial collagen-
ase (MMP-1) or stromelysin-1 (MMP-3) readily detectable in 
any of the crude BAL fluids tested. 
3.3. Overall type IV collagenase and elastase activities in BAL 
samples 
Global type IV collagenase activity in BAL fluid was tested 
by using radiolabelled type IV collagen as substratum. Only 
BAL from LPS plus PMA-treated animals fully degraded type 
IV collagen. To further analyse the type of proteolytic activity 
involved in this degradation, the assay was carried out in the 
presence of either an inhibitor of MMPs (batimastat at 100 
nM), an inhibitor of serine proteinases (benzamidine at 
1 mM), or a specific inhibitor of elastase (S 18465 at 100 
nM) added in vitro after BAL fluid recovery. Only batimastat 
completly inhibited the ex vivo degradation of type IV colla-
gen mediated by BAL from LPS plus PMA-treated animals 
(not shown). 
Elastase activity in BAL fluid only increased significantly in 
the group of hamsters treated sequentially with LPS and 
PMA (Table 2). This activity was totally inhibited with the 
selective neutrophil elastase inhibitor, S 18465. Furthermore, 
no inhibition was observed with the metal chelator EDTA. 
the BAL fluids from animals treated with LPS followed by 
PMA and S 18465 administration were assayed on the degra-
dation of type IV collagen, a total inhibition of this degrada-
tion was observed. 
3.5. Elastase can activate 92 kDa pro-MMP-9 into a 75 kDa 
species 
When recombinant pro-MMP-9 is incubated with purified 
elastase, a major gelatinolytic activity at 75 kDa is then de-
tected by zymography (Fig. 3A). On the other hand, treat-
ment of pro-MMP-9 with APMA gave two intermediate spe-
cies at 78 and 71 kDa and a 65 kDa entity. Elastase alone 
3.4. Influence of neutrophil elastase inhibition in vivo on ex vivo 
gelatinase and type IV collagenolytic activities 
Hamsters receiving LPS and PMA were treated intratra-
cheally with S 18465, concomitantly with PMA. In zymogra-
phy, the 75 kDa gelatinase activity was considerably reduced 
in the treated group (Fig. 2). No major differences were ob-
served for the other forms of gelatinases. In addition, when 
Fig. 3. A: Activation of human recombinant pro-MMP-9 by 
APMA or elastase as studied by zymography. MMP-9 was incu-
bated with either APMA for 1 h or human elastase for 24 h. B: 
Peptidomimetic substrate degradation by human pro-MMP-9 acti-
vated by APMA or elastase. The activity is expressed as fluores-
cence units of the cleaved substrate after 10 min incubation. 
114 G. Ferry et al.lFEBS Letters 402 (1997) 111-115 
exhibited no activity. To assay the functional status of elas-
tase-activated pro-MMP-9, a synthetic substrate was used. 
Incubation with elastase was found to be more potent than 
APMA in activating the otherwise unreactive pro-MMP-9 
(Fig. 3B). Again elastase alone was inactive in this assay. 
4. Discussion 
The main enzymes involved in the proteolysis of the ECM 
in acute lung injury are serine proteases, namely leucocyte 
elastase, and matrix metalloproteinases [2]. In a tentative rep-
resentative model of acute lung injury we have attempted to 
delineate the inter-relationship between two proteolytic en-
zymes produced by the neutrophils, i.e., neutrophil elastase 
and the 92 kDa gelatinase B or MMP-9. The in vitro and 
in vivo experiments carried out in this study suggest that 
neutrophil elastase is a physiological activator of pro-MMP-
9 converting it into a 75 kDa species associated with collage-
nolytic potential. 
Acute lung injury in hamster was induced by intratracheal 
administration of LPS causing a massive PMN recruitment in 
the lung, followed by an exogenous cell activation with PMA. 
During the first phase after instillation of LPS, corresponding 
to the PMN influx, only small amounts of 92, 65 and 63 kDa 
gelatinases are recovered in BAL fluid. In addition, based on 
the level of haemoglobin content, this procedure was unable 
to induce acute lung injury in hamsters. Previous results in a 
guinea-pig model have demonstrated that the BAL fluid of 
LPS-treated animals exhibits an increase in MMP-9 mostly 
in its inactive 92 kDa proform [7]. However, in this model, 
a global gelatinolytic activity in the BAL fluid was detected 24 
h after LPS instillation. In the hamster model, despite massive 
PMN influx to the lung, we were unable to detect an increase 
in gelatinolytic activity in the BAL fluid suggesting that 
PMNs were not activated during recruitment in this species 
and under our experimental conditions. 
Hamster treatment with PMA which can mobilise the ter-
tiary granules of PMNs containing the 92 kDa MMP-9 gelat-
inase in vitro (data not shown) ensured PMN activation and 
correlated with a marked overexpression of an elastolytic ac-
tivity with properties similar to neutrophil elastase, and of a 
92 kDa gelatinase with properties similar to pro-MMP-9 
along with 65 and 63 kDa gelatinases and the appearance of 
a 75 kDa gelatinase. Both MMP-9 and elastase are produced 
by PMNs, and these cells were recruited and activated in our 
model. Thus the two proteases detected in BAL fluids are 
likely to be neutrophil-derived. 
It is not clear whether the 65 and 63 kDa gelatinolytic 
activities are related to MMP-2 or not. However, it is clear 
that the levels expressed did not correlate with an overall 
collagenolytic activity in BAL fluids. 
In contrast, the emergence of a 75 kDa activity — and its 
level of expression — found in the gelatinolytic profiles after 
LPS and PMA activation correlated with the ability of the 
corresponding BAL to degrade type IV collagen ex vivo. 
Both activities — global or separated on a zymogram — 
were inhibited by MMP inhibitors. 
At this point, at least two hypotheses could be put forward 
in an attempt to explain the presence of this 75 kDa activity: 
(i) based on its molecular weight, it may be a gelatinase sim-
ilar to MMP-2 or MMP-8 although the latter is at least 10 
times less potent than MMP-2 and MMP-9 in the degradation 
of gelatin [16,17] and MMP-2 is not produced by PMNS, or 
(ii) the 75 kDa species might be a degradation or activation 
product of the 92 kDa gelatinase. Additionally, assuming that 
this 75 kDa gelatinase is responsible for ECM degradation, it 
must be an active form. 
Our results and previously published studies suggest an af-
filiation between the 75 kDa activity and the 92 kDa pro-
MMP-9. Two physiological protease activators of MMPs 
are present in BAL fluids from ARDS patients: tissue kallik-
rein, a very efficient activator of MMP-9 [18], and elastase 
[19]. We did not titrate kallilrein levels in our model but 
elastase is present at high levels in BAL concomitantly with 
the 75 kDa gelatinase. Secondly, we verified that under our 
experimental conditions, purified recombinant pro-MMP-9 in-
cubated in vitro with purified leukocyte elastase produces a 75 
kDa gelatinase species, and this transformation correlates 
with a more active and distinct species than after activation 
by APMA. Finally, in vivo, a potent and specific leucocyte 
elastase inhibitor, S 18465 [11], prevents the appearance of 
this 75 kDa gelatinase concomitantly with a loss of ex vivo 
type IV collagen degradation. 
In conclusion, it is suggested that neutrophil-derived elas-
tase induces activation of MMP-9 in this animal model of 
acute lung injury. In addition to previous in vitro work show-
ing that neutrophil elastase converts stromelysin-1 (MMP-3) 
[17] and metalloelastase (MMP-12) [19] into active enzymes 
and allows activation of MMP-9 by selective destruction of its 
specific endogenous inhibitor TIMP-1 [20], the present study 
emphasises, using an in vivo model, the interrelationship be-
tween neutrophil elastase and the MMP family. Also it sug-
gests that neutrophil elastase may play an important role in in 
vivo ECM destruction not only by its direct action on lung 
connective tissue components like elastin, but also by convert-
ing pro-MMP-9 into an active form exhibiting type IV colla-
genase activity. The ability of neutrophils to activate gelati-
nase by either a reactive oxygen-dependent or independent 
pathway has already been shown in vitro [9]. We further dem-
onstrate that in vivo, neutrophil elastase might be the reactive 
oxygen species-independent pathway leading to gelatinase B 
activation. 
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